Directory
Serafin Morales Murillo

Serafin Morales Murillo

Degree: PhD

973 70 53 03
smorales.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/L-7216-2019

Groups

Publications

  • Martín M; González-Rivera M; Morales S; de la Haba-Rodriguez J; González-Cortijo L; Manso L; Albanell J; González-Martín A; González S; Arcusa A; de la Cruz-Merino L; Rojo F; Vidal M; Galván P; Aguirre E; Morales C; Ferree S; Pompilio K; Casas M; Caballero R; Goicoechea U; Carrasco E; Michalopoulos S; Hornberger J; Prat A

    Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

    Current Medical Research and Opinion 31 1129-1137. .

    [doi:10.1185/03007995.2015.1037730]

  • Martín M; Loibl S; von Minckwitz G; Morales S; Martinez N; Guerrero A; Anton A; Aktas B; Schoenegg W; Muñoz M; Garcia-Saenz JÁ; Gil M; Ramos M; Margeli M; Carrasco E; Liedtke C; Wachsmann G; Mehta K; De la Haba-Rodriguez JR

    Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

    Journal of Clinical Oncology 33 1045-1045. .

    [doi:10.1200/JCO.2014.57.2388]

  • Salazar, R.; Morales, S.; Gil-Martín, M.; Aguirre, E.; Oaknin, A.; Garcia, M.; Callies, S.; Wickremsinhe, E.R.; Benhadji, K.A.; Llombart, A.

    Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors

    CANCER CHEMOTHERAPY AND PHARMACOLOGY 73 1205-1215. .

    [doi:10.1007/s00280-014-2457-1]

  • Aguirre, E.; Morales, S.; Llombart, A.

    Other malignancies I. breast cancer

    Other Malignancies I. Breast Cancer 235-251. .

  • Sanchez-Rovira, P.; Segui, M. A.; Llombart, A.; Aranda, E.; Anton, A.; Sanchez, A.; Lomas, M.; Jaen, A.; Fernandez, M.; Porras, I.; Dalmau, E.; Morales, S.; de la Haba-Rodriguez, J.

    Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

    CLINICAL & TRANSLATIONAL ONCOLOGY 15 810-817. .

    [doi:10.1007/s12094-013-1006-4]

  • Aguirre E; Taberner T; Luaña A; Morales S; Llombart A

    Severe thrombocytopenia related to long-term trastuzumab exposure.

    Tumori 99 -. .

    [doi:10.1700/1248.13801]

  • Martin, Miguel; Segui, Miguel A.; Anton, Antonio; Ruiz, Amparo; Ramos, Manuel; Adrover, Encarna; Aranda, Ignacio; Rodriguez-Lescure, Alvaro; Grosse, Regina; Calvo, Lourdes; Barnadas, Agusti; Isla, Dolores; Martinez del Prado, Purificacion; Ruiz Borrego, Manuel; Zaluski, Jerzy; Arcusa, Angels; Munoz, Montserrat; Lopez Vega, Jose M.; Mel, Jose R.; Munarriz, Blanca; Llorca, Cristina; Jara, Carlos; Alba, Emilio; Florian, Jesus; Li, Junfang; Lopez Garcia-Asenjo, Jose A.; Saez, Amparo; Jose Rios, Maria; Almenar, Sergio; Peiro, Gloria; Lluch, Ana; GEICAM 9805 Investigators

    Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.

    NEW ENGLAND JOURNAL OF MEDICINE 363 2200-2210. .

    [doi:10.1056/NEJMoa0910320]

  • Aguirre Ortega, E.; Martín Marco, A.; Canal Sotelo, J.; Morales Murillo, S.; Llombart Cussac, A.

    Dyspnea and persistent cough as first signs of distant recurrence disease

    MEDICINA DE FAMILIA-SEMERGEN 36 597-599. .

    [doi:10.1016/j.semerg.2010.02.011]

  • Rosell, Rafael; Moran, Teresa; Queralt, Cristina; Porta, Rut; Cardenal, Felipe; Camps, Carlos; Majem, Margarita; Lopez-Vivanco, Guillermo; Isla, Dolores; Provencio, Mariano; Insa, Amelia; Massuti, Bartomeu; Luis Gonzalez-Larriba, Jose; Paz-Ares, Luis; Bover, Isabel; Garcia-Campelo, Rosario; Angel Moreno, Miguel; Catot, Silvia; Rolfo, Christian; Reguart, Noemi; Palmero, Ramon; Miguel Sanchez, Jose; Bastus, Roman; Mayo, Clara; Bertran-Alamillo, Jordi; Angel Molina, Miguel; Javier Sanchez, Jose; Taron, Miquel; Spanish Lung Canc Grp

    Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.

    NEW ENGLAND JOURNAL OF MEDICINE 361 958-38. .

    [doi:10.1056/NEJMoa0904554]

  • Baselga, J; Carbonell, X; Castaneda-Soto, NJ; Clemens, M; Green, M; Harvey, V; Morales, S; Barton, C; Ghahramani, P

    Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule

    Journal of Clinical Oncology 23 2162-2171. .

    [doi:10.1200/JCO.2005.01.014]

  • Espinosa, E; Morales, S; Borrega, P; Casas, A; Madronal, C; Machengs, I; Illarramendi, J; Lizon, J; Moreno, J; Belon, J; Janariz, J; de la Puente, M; Checa, T; Mel, JR; Baron, MG

    Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer

    CANCER CHEMOTHERAPY AND PHARMACOLOGY 54 546-552. .

    [doi:10.1007/s00280-004-0830-1]

  • Morales, S; Lorenzo, A; Ramos, M; Ballesteros, P; Mendez, M; Almanza, C; Castellanos, J; Moreno-Nogueira, JA; Casal, J; Lizon, J; Oltra, A; Frau, A; Machengs, I; Galan, A; Belon, J; Llorca, C

    Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

    CANCER CHEMOTHERAPY AND PHARMACOLOGY 53 75-81. .

    [doi:10.1007/s00280-003-0690-0]

Projects

  • Development of Computer Application (Apps) for Information and Monitoring of Patients with Breast Cancer at the Hospital Arnau de Vilanova De Lleida
  • SELECCIÓN DE TRATAMIENTO CON QUIMIOTERAPIA NEOADYUVANTE EN PACIENTES CON CÁNCER DE MAMA EN ESTADIO PRECOZ Y CON RECEPTORES HORMONALES POSITIVOS MEDIANTE LA DETERMINACIÓN DE LA PLATAFORMA ONCOTYPE, CF DNA EN SANGRE PERIFÉRICA Y CAMBIOS DEL MARCADOR KI67 EN TEJIDO TUMORAL.
  • Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante